Navigation Links
Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, presented first-time data from a pre-clinical study evaluating the toxicity and antitumor effect of nab-rapamycin (ABI-009), an albumin-bound mTOR kinase inhibitor, at the 98th American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2007 in Los Angeles. Results from the pre-clinical study demonstrated that nab-rapamycin was well-tolerated, showed linear pharmacokinetics, and was highly effective against a number of tumor models in vivo. (Abstract #4719; Nanoparticle Albumin-bound (nab) Rapamycin as an Anticancer Agent).

Leveraging Nab Technology with Rapamycin to Target mTOR Pathway

The mammalian target of rapamycin (mTOR) is a cell-signaling protein that regulates the response of tumor cells to nutrients and growth factors, as well as controls tumor blood supply through effects on vascular endothelial growth factor (VEGF). Rapamycin is an mTOR inhibitor. The mTOR pathway is thought to be overactivated in numerous tumors and plays a critical role in cell survival and resistance to chemotherapy. Inhibition of mTOR activity prevents the signaling to important pathways that control cell growth and lead to a lowering of VEGF levels, thus decreasing the ability of tumors to gain their own blood supply (angiogenesis).

The role of mTOR inhibition has led investigators at Abraxis to explore the use of the nanoparticle albumin-bound (nab(TM)) tumor-targeting technology to enhance the deregulation of mTOR signaling. Nab-rapamycin is also intended to address limitations posed by the poor water solubility of rapamycin and may enable higher concentrations of the drug to reach the tumor tissue. Abraxis plans to commence Phase I clinical trials with nab-rapamycin in 2007.

Abraxis continues to explore the role of nab technology for targeting SPARC an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:9/30/2014)... 30, 2014 Arbor Pharmaceuticals, LLC. - ... Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product ... the Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Arbor Pharmaceuticals, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... , Sept. 30, 2014  According to their ... of cancer clinical trials is going through a ... and the work of the current clinical trial ... of ,next generation, clinical trials, which will ultimately ... The company has been recognized by ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... , April 27, 2010 Shire plc (LSE: ... it has received a Paragraph IV Notice Letter from Anchen,Pharmaceuticals, ... Application ("ANDA") for a generic version of Shire,s 1 mg, ... tablets, INTUNIV(TM).,Shire had previously reported in March 2010 ...
... April 27 For a second consecutive year, following the ... Auto Thefts) is cautioning Michigan drivers, and now auto dealers ... theft-related crimes.   , , ... increased vehicle security features, and the continuing success of Michigan ...
Cached Medicine Technology:Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 2Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen 3H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 2H.E.A.T. Warns Drivers, Auto Dealers of Continuing Trend in Unconventional Auto Crimes 3
(Date:10/1/2014)... Despite a policy focus on expanding access to ... population continues to have significant dental disease. In ... the American Dental Association , researchers from Tufts ... of Dental Medicine report on the first large-scale ... provided by caregivers to adults with developmental disabilities. ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Bedros ... Fit Body Boot Camp fitness boot camps, he’s also ... personal training , with sold out business summits, a ... as marketing consultant to a recent Spike TV reality ... says that now is the time for personal trainers ...
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
(Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... at the University of Iowa Roy J. and Lucille A. ... (PET) technology can help // doctors gauge the response of ... and co-author Bruce Cheson, M.D., of the Lombardi Comprehensive Cancer ... usage of PET n gauging the response of the tumor ...
... loan of $ 260 M to Kenya by the World ... be in rough weather as it has been delayed due ... ,The corruption charges are against the Kenyan government, the ... ,According to the Kenyan Ministry of Health in February 2005 ...
... Biocon, an Indian biotechnology company will raise its investments ... destination for clinical development of drugs. Biocon is reported ... with life sciences organizations in Scotland. There are more ... than 26,500 people. Scotland will serve to fill the ...
... Won Jang of the Department of Internal Medicine at the ... that administering an antiviral drug would help prevent hepatitis ... treatment of cancer. ,In hepatocellular carcinoma (HCC), patients ... a result of chemotherapy. Hepatocellular carcinoma or liver cancer is ...
... has found prominence again, for the wrong reasons. Blaming the ... // held the post of Chief Scientific Officer at ... the risks of MMR triple vaccine adequately, despite a lurking fear ... if this doubt is proved, it could turn out to be ...
... implantation of stem cells into the pancreas of type 2 ... endogenous insulin. // In addition, it has been associated with ... decrease in blood sugar levels. ,If approved, this ... diabetics from receiving insulin or drugs to stimulate the production ...
Cached Medicine News:Health News:Hepatitis B Relapse In Cancer Chemotherapy Can Be Avoided By Antiviral Drug 2
... testing your blood glucose regularly, you want ... possible. Conventional spring-loaded lancet systems often penetrate ... cause painful dilation or tearing of skin ... a precise, linear action that provides greater ...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,410-0) or contact custom...
... models cover the range from 2ul to 5000ul. ... Volume lock design prevents inadvertent volume change. ... Whole pipette is autoclavable at 121C(250F). ... polypropylene. Suitable for one-handed operation. Auto ...
Medicine Products: